Our Expertise
Partnership Strategy
Development and management of R&D alliances
Health research and innovation are high-risk and resource-intensive, and multidisciplinary, multisector partnerships are increasingly pivotal to sharing risk, sustaining efforts, diversifying opportunities and achieving impact. Developing a successful alliance requires creativity and empathy: the creativity to build collaborative models that reflect the unique needs of the partners and embed the resilience to thrive in a rapidly changing research landscape; the empathy to engage with diverse personalities, find common ground and coalesce parties around a shared mission.
Shift Health advises some of the world’s most complex and ambitious R&D alliances and brings a deep understanding of the intricacies involved in brokering, mobilizing and governing partnerships that span sectors, disciplines and geographies. Our work across the health innovation ecosystem affords us an appreciation of the perspectives of groups with divergent agendas; an ability to align common interests and build consensus where objectives compete; and the experience to create durable decision-making structures that foster clarity, fairness and accountability.
Partnership Evaluation – Partnership Governance – Alliance Management
Advancing a Bold Model to Combat Pandemic and Biological Threats
Recognizing that our traditional models to pandemic preparedness have failed to imagine the risk and broad societal impact of biological threats, McMaster University sought support to establish a new way forward.
Building the Case for Biopharma Industry Investment in Strep A Vaccine Development
A global health consortium required support in attracting greater industry investment into the traditionally underfunded area of Strep A vaccine development.
Leveraging External Partnerships to Maximize the Value of a Top-5 Pharma’s Portfolio
In the face of constrained R&D budgets, a top-5 pharmaceutical company needed support to develop a transformative, corporate-wide strategy to assess and secure external funding.
De-Risking Vaccine Development Through a Translational Research Public-Private Partnership
Facing the need to de-risk the development of new vaccines, a top-10 biopharma company required help articulating the strategic vision and business case for a translational research public-private partnership.
Ensuring the World is Ready for the World’s First HIV Vaccine
The Pox-Protein Public-Private Partnership (P5) is tackling an enduring and daunting challenge: developing the world’s first HIV vaccine and ensuring it achieves maximum public health impact.
Accelerating the Development of MERS-CoV Technologies
The International Vaccine Institute in South Korea and the Saudi Ministry of Health required strategic and facilitation support to advance a collaborative approach to MERS-CoV vaccine development.